RxDoctor Payments Data

Prakash Chand, MD

Internal Medicine · Elyria, OHNPI 1275812497

Payments from drug & device makers

$1,082in general payments, 2019–2025

Across 30 payments — averaging $36.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$396
  • AbbVie$138
  • GSK$121
  • Inspire Medical Systems, Inc.$94
  • Bayer$91
  • Ascendis Pharma Endocrinology Inc$55
  • plus $186 from 8 others

What the payments were for

  • Food & beverage$1,082100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,082 in reported general payments places this provider in the 75th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$90,000
Medicare patients
324
Services billed
890

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RezdiffraResmetirom18$89,764
XifaxanRifaximin27$83,417
Ursodiol73$8,817
EliquisApixaban14$7,991
Azathioprine40$1,477
Nadolol25$1,354
Lactulose27$1,077
Pantoprazole Sodium135$862
Spironolactone87$436
Metformin Hcl56$324
Furosemide69$212
Rosuvastatin Calcium28$171
Atorvastatin Calcium44$165
FenofibrateFenofibrate Nanocrystallized16$161
Cefdinir17$142

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Madrigal PharmaceuticalsRezdiffra$14$89,76418 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$35$83,41727 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Elyria

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →